Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

Published: 2026-04-27 07:05:29 ET SNDX

Published on 04/27/2026 at 07:05 am EDT

NEW YORK - Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, April 30, 2026.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following

Conference ID: Syndax1Q26

Domestic Dial-in Number: 800-590-8290

International Dial-in Number: 240-690-8800

Live webcast: https://sndx-1q26.open-exchange.net

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment.

Contact:

Sharon Klahre

Email: [email protected]

Tel: 781.684.9827